What is a stock summary page? Click here for an overview.
Business Description
Cormedix Inc
NAICS : 325412
SIC : 2834
ISIN : US21900C1009
Compare
Compare
Traded in other countries / regions
CRMD.USA19KA.Germany Index Membership
Russell 2000Russell 3000Russell 2000 IPO Date
2010-05-13Description
Cormedix Inc is a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions. The Company's focus is on the commercialization of its product, DefenCath, in the United States (U.S.) and other key markets. The group currently operates in a single segment, Drug Product, located in a single geographic location, the United States.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 99.98 | |||||
| Equity-to-Asset | 0.71 | |||||
| Debt-to-Equity | 0.01 | |||||
| Debt-to-EBITDA | -0.03 | |||||
| Piotroski F-Score | 3/9 | |||||
| Altman Z-Score | 3.62 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 428.5 | |||||
| 3-Year EBITDA Growth Rate | 25.5 | |||||
| 3-Year EPS without NRI Growth Rate | 26.3 | |||||
| 3-Year FCF Growth Rate | -12.9 | |||||
| 3-Year Book Growth Rate | -7.3 | |||||
| Future 3-5Y Total Revenue Growth Rate Estimate | 79.1 |
Momentum Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 17.69 | |||||
| 9-Day RSI | 20.58 | |||||
| 14-Day RSI | 25.68 | |||||
| 3-1 Month Momentum % | 17.24 | |||||
| 6-1 Month Momentum % | 15.68 | |||||
| 12-1 Month Momentum % | 132.2 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 3.39 | |||||
| Quick Ratio | 3.16 | |||||
| Cash Ratio | 1.53 | |||||
| Days Inventory | 519.01 | |||||
| Days Sales Outstanding | 193.8 | |||||
| Days Payable | 309.18 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -19.1 | |||||
| Shareholder Yield % | -4.71 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 92.66 | |||||
| Operating Margin % | -51.43 | |||||
| Net Margin % | -41.25 | |||||
| FCF Margin % | -116.7 | |||||
| ROE % | -28.22 | |||||
| ROA % | -22.18 | |||||
| ROIC % | -175.93 | |||||
| 3-Year ROIIC % | 24.11 | |||||
| ROC (Joel Greenblatt) % | -191.84 | |||||
| ROCE % | -30.15 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Forward PE Ratio | 10.78 | |||||
| PS Ratio | 8.55 | |||||
| PB Ratio | 4.66 | |||||
| Price-to-Tangible-Book | 4.73 | |||||
| EV-to-EBIT | -18.64 | |||||
| EV-to-EBITDA | -18.94 | |||||
| EV-to-Revenue | 8.27 | |||||
| EV-to-Forward-Revenue | 2.89 | |||||
| EV-to-FCF | -7.09 | |||||
| Price-to-Net-Current-Asset-Value | 4.88 | |||||
| Price-to-Net-Cash | 22.59 | |||||
| Earnings Yield (Greenblatt) % | -5.36 | |||||
| FCF Yield % | -12.76 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:CRMD
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Cormedix Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 43.472 | ||
| EPS (TTM) ($) | -0.33 | ||
| Beta | 1.41 | ||
| 3-Year Sharpe Ratio | 0.65 | ||
| 3-Year Sortino Ratio | 1.08 | ||
| Volatility % | 80.8 | ||
| 14-Day RSI | 25.68 | ||
| 14-Day ATR ($) | 0.713747 | ||
| 20-Day SMA ($) | 9.2115 | ||
| 12-1 Month Momentum % | 132.2 | ||
| 52-Week Range ($) | 3.61 - 13.85 | ||
| Shares Outstanding (Mil) | 65.18 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Cormedix Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Cormedix Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Cormedix Inc Frequently Asked Questions
What is Cormedix Inc(CRMD)'s stock price today?
The current price of CRMD is $6.10. The 52 week high of CRMD is $13.85 and 52 week low is $3.61.
When is next earnings date of Cormedix Inc(CRMD)?
The next earnings date of Cormedix Inc(CRMD) is 2025-05-09 Est..
Does Cormedix Inc(CRMD) pay dividends? If so, how much?
Cormedix Inc(CRMD) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers